Samuel lab publications
Selected highlight publications
- Li Y, Hunter A, Wakeel MM, Sun G, Lau RWK, Broughton BRS, Pino IEO, Deng Z, Zhang T, Murthi P, Del Borgo MP, Widdop RE, Polo JM, Ricardo SD*, Samuel CS*. 2024. The renoprotective efficacy and safety of genetically-engineered human bone marrow-derived mesenchymal stromal cell expressing anti-fibrotic cargo. Stem Cell Research & Therapy 15, 375
- Chakraborty A, Wang C, Hodgson-Garms M, Broughton BRS, Frith JE, Kelly K, Samuel CS*. 2024. Induced pluripotent stem cell-derived mesenchymal stem cells reverse bleomycin-injured pulmonary fibrosis and related lung stiffness. Biomedicine & Pharmacotherapy 178, 117259
- Truong S, Bonnici B, Rupasinghe S, Kemp-Harper BK, Samuel CS*, Broughton BRS*. 2023. Post-stroke administration of H2 relaxin reduces functional deficits, neuronal apoptosis and immune cell infiltration into the mouse brain. Pharmacological Research 187, 106611
- Li Y, Zheng G, Salimova E, Broughton BRS, Ricardo SD, de Veer M, Samuel CS*. 2023. Simultaneous late-gadolinium enhancement and T1 mapping of fibrosis and a novel cell-based combination therapy in hypertensive mice. Biomedicine & Pharmacotherapy 158, 114069
- Chakraborty A, Pinar AA, Lam M, Bourke JE, Royce SG, Selomulya C*, Samuel CS*. 2021. Pulmonary myeloid cell uptake of biodegradable nanoparticles conjugated with an anti-fibrotic agent provides a novel strategy for treating chronic allergic airways disease. Biomaterials 273, 120796
- Wang C, Gaspari TA, Ferens D, Spizzo I, Kemp-Harper BK*, Samuel CS*. 2021. Simultaneous targeting of oxidative stress and fibrosis abrogates cardiomyopathy-induced ventricular remodelling and dysfunction. British Journal of Pharmacology 178, 2424-2442
*Corresponding author.
Additional publications
A full list of Samuel Lab publications can be viewed on PubMed.